An important new paper in the Journal of Vascular and Interventional Radiology has just provided us with the first large set of data on the outcomes of men with prostate cancer treated with focal laser ablation (FLA). … READ MORE …
Filed under: Uncategorized | Tagged: ablation, focal, intermediate risk, laser, localized, low risk | 3 Comments »
The ability to “manage” patients’ satisfaction with their care in the treatment of localized prostate cancer is challenging — for patients, for caregivers, for physicians, and for health systems. … READ MORE …
Filed under: Uncategorized | Tagged: choice, decision, PreProCare, regret, satisfaction, tool, Treatment, trial | Leave a comment »
Conventional wisdom (dating back to the 1940s) has long been that giving testosterone supplements to men who had been treated for prostate cancer is a really bad idea. … READ MORE …
Filed under: Uncategorized | Tagged: hypogonadal, replacement, serum, testosterone, TRT | 2 Comments »
Active surveillance and its role in the management of lower-risk forms of prostate cancer, and related issues like MRI scanning, were clearly key topics of attention at the annual meeting of the European Association of Urology in Barcelona over the weekend. … READ MORE …
Filed under: Uncategorized | Tagged: active, annual meeting, EAU, surveillance | Leave a comment »
A new paper just published in PLOS Medicine describes the development of a new online tool called PREDICT Prostate. … READ MORE …
Filed under: Uncategorized | Tagged: caclulator, nomogram, predict, predictor, prognosis, prostate, tool | 9 Comments »
As many readers will remember, Prostvac is an active immunotherapeutic vaccine that — some years ago — had shown promising results in a randomized Phase II clinical trial. … READ MORE …
Filed under: Uncategorized | Tagged: clinical, Prostvac, trial | 1 Comment »
